Fig. 3

Responder analyses. The graphics show, among patients treated with daridorexant 50 mg or placebo, a the proportion of IDSIQ responders at each timepoint; b the percentage of IDSIQ responders by number of weeks with a response; c cumulative proportions of patients with a response over a consecutive number of weeks (maximum). A patient was defined as a ‘responder’ if the decrease from baseline in IDSIQ total score at a given timepoint was ≥ 20-points. IDSIQ, Insomnia Daytime Symptoms and Impacts Questionnaire